GlobeNewswire

European Consumers Embrace Elixinol Hemp Oil CBD as Part of Wellness Movement

Dela

Elixinol Brand Cannabidiol Hemp Oil Now Available Throughout Europe

DENVER, July 19, 2017 (GLOBE NEWSWIRE) -- Already regarded as one of the fastest growing and most trusted cannabidiol brands in the world, Elixinol announces expansion into Europe.

Photos accompanying this announcement are available at:

http://www.globenewswire.com/NewsRoom/AttachmentNg/9918871c-5c3d-4974-8039-2c687211b538

http://www.globenewswire.com/NewsRoom/AttachmentNg/187d5574-95f9-40d9-8e22-061d660fd2a6

http://www.globenewswire.com/NewsRoom/AttachmentNg/0978ad48-d660-4b86-b161-e457289c8402

http://www.globenewswire.com/NewsRoom/AttachmentNg/21045979-c22e-488c-8084-fdaaefb284a4

Seven Elixinol hemp oil CBD products will be available to consumers throughout Europe including best-sellers such as Liposomes, noted for their great taste and increased bioavailability, the targeted topical Rescue Balm, and CBD capsules.

Consumers throughout the world use Elixinol's CBD hemp oil for both lifestyle improvement and condition treatment. Elixinol expects Europeans will embrace CBD hemp oil products as part of an overall wellness regimen.

"Faced with shrinking healthcare budgets and an increased emphasis on well-being, European consumers are looking for ways to get better rest, reduce stress and optimize their fitness efforts," said Husong.

With increasing numbers of consumers in Europe embracing fitness, organic foods and stress reduction, Elixinol's market entry meets the needs of the growing marketplace.

According to Statista, over 52% of Western Europeans rated their own health knowledge as sufficient or excellent, "translating into greater understanding of health measures and what individuals should do to improve their own health." The health and wellness market value in Western Europe is already over 145 million euros with more growth projected. Western Europe's dietary supplement market is projected to reach over 5.6 million euros by 2020. 

"From executives who crave increased focus and stress reduction to fitness aficionados seeking faster recovery, since we launched, sales in Europe have exceeded our aggressive expectations," said Chris Husong, Director of Global Marketing and Sales for Elixinol.

"Hemp and its benefits are nothing new for Europeans," said Marco Cappiello, Director of European Operations for Elixinol. "But with concerns over serving size, potency and purity now addressed by Elixinol's rigorous and transparent testing process, Europeans can now purchase CBD hemp oil with confidence," he continued.

To eliminate consumer concerns about metals, solvents, pesticides as well as potency and purity, Elixinol is the only global brand to post independent laboratory test results online and follows a strict pharmaceutical-grade testing process.

Elixinol will source its European CBD from existing relationships with Northern European organic farmers who have been cultivating hemp for generations.

"It's as if we're coming home," said Husong. "We've had relationships in Europe since our inception, being able to deliver the end product to the European consumer is incredibly satisfying."

Elixinol products are available to customers in Europe on elixinol.com and in various retail health outlets throughout Spain and Italy.

About Elixinol: 
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol distributes CBD products in 22 countries globally including United States, Japan, Puerto Rico, Brazil and throughout Europe. More information available at Elixinol.com.

Photos may also be available via AP PhotoExpress.

Media Contact: 
Chris Husong
Elixinol
+1 844-804-3504 ext 420
chris@elixinol.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elixinol via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum